You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Avacta announces clinical study of AVA6000

Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability

Avacta Group – which develops oncology drugs based on its Affimer and pre|CISION platforms – has announced that the first-in-human phase 1 trial of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients, following a positive review of safety and tolerability data.